Related Experiment Video
Updated: Jun 24, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
[Molecular diagnosis of and molecular targeting therapy for leukemia]
1Department of Clinical Pathology, Juntendo University of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan. tabe@juntendo.ac.jp
Abstract:
A number of molecular targets have been identified in leukemia, based on the understanding of signaling pathways controlling cell differentiation, proliferation, apoptosis, and malignant transformation. Growth factors and integrins interact with their receptors and activate signaling cascades with intimate interconnections. The specific niches within the bone marrow microenvironment may provide a sanctuary for subpopulations of leukemic cells to escape chemotherapy-induced death and acquire drug resistance. Investigations into bone marrow stroma-leukemia crosstalk may result in the development of strategies against the acquisition of a chemo-resistant phenotype and enhance the efficacy of therapies in leukemia. In recent studies, we proposed novel therapeutic interventions targeting the microenvironment/leukemia interaction focusing on SDF1/CXCR4, ILK/PI3K/Akt, TGF-beta, and Notch signaling. Gene transcriptional activity is regulated by chromatin modification and DNA methylation. Nuclear receptors such as RAR, RXR, and PPARgamma exert histone acetyl transferase activity (HAT). The transcription of target genes is initiated following the ligation of these receptors, recruitment of co-activators, and replacement of repressors. We demonstrated that histone acetylation by the PPARgamma agonist CDDO, RAR/RXR agonist ATRA, and/or histone deacetylase inhibitors (HDACIs) reversed the silenced RARbeta and MDR1 genes in acute promyelocytic leukemia, and that HDACI induced apoptosis with phagocytosis through the induction of Annexin A1 in AML1/ETO-positive acute myelocytic leukemia (AML) cells. The translation of research findings into effective clinical laboratory tests is an important approach. The flow cytometric technique is a powerful tool in the field of clinical laboratory medicine, with its accurate and rapid analysis. We carried out phospho-specific flow cytometry to investigate protein phosphorylation in AML cells and detect ZAP-70 in chronic lymphocytic leukemia cells, including the evaluation of antibodies, staining epitopes, fixing and permeabilizing methods, and analyzing systems. Finally, we emphasize the potential applications of research findings and methods in the fields of clinical medicine, molecular diagnosis, and targeting therapy.
Insights
Targeting leukemia cell signaling pathways and the bone marrow microenvironment can overcome drug resistance. Novel therapies involving histone acetylation and flow cytometry show promise for leukemia treatment and diagnosis.
Area of Science:
- Molecular biology
- Cancer research
- Hematology
Context:
- Leukemia cell survival is influenced by signaling pathways and the bone marrow microenvironment.
- Leukemic cells can develop chemo-resistance within specific bone marrow niches.
- Understanding leukemia-stroma interactions is crucial for developing effective therapies.
Purpose:
- To investigate novel therapeutic interventions targeting microenvironment/leukemia crosstalk.
- To explore the role of chromatin modification and nuclear receptors in gene regulation in leukemia.
- To evaluate the utility of phospho-specific flow cytometry in leukemia diagnosis and research.
Summary:
- Therapeutic strategies targeting SDF1/CXCR4, ILK/PI3K/Akt, TGF-beta, and Notch signaling pathways are proposed.
- Histone acetylation using PPARgamma agonist CDDO and RAR/RXR agonist ATRA, along with histone deacetylase inhibitors (HDACIs), can reverse gene silencing and induce apoptosis in leukemia cells.
- Phospho-specific flow cytometry is utilized to analyze protein phosphorylation in acute myeloid leukemia (AML) and detect ZAP-70 in chronic lymphocytic leukemia (CLL).
Impact:
- Findings may lead to the development of strategies to overcome chemo-resistance in leukemia.
- Research contributes to understanding gene regulation in leukemia through chromatin modification.
- Flow cytometry applications enhance molecular diagnosis and targeted therapy for leukemia patients.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

